Floatz logo

tng260

Solid Tumors, Adult

Tango Therapeutics, Inc.Phase 1/2Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Solid Tumors, Adult cohort.

Asset / SponsorPhaseRating
Zoladex
Eli Lilly and Company
Phase 1/2CC
TAMOXIFEN
Eli Lilly and Company
Phase 1/2CC
Letrozole
Eli Lilly and Company
Phase 1/2CC
Cyclophosphamide
Tango Therapeutics, Inc.
Phase 1/2CC
Tersolisib
Eli Lilly and Company
Phase 1/2CC

View all 38 →

Same molecule, other indications

tng260 is also rated in:

lung adenocarcinomaDormant
CC
Indicative ·
45 / 100
View asset →
non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
lung cancerDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →